{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:52:24Z","timestamp":1793778744455,"version":"4.6.1"},"reference-count":89,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/501100022795","name":"Hamilton Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30-AG024824"],"award-info":[{"award-number":["P30-AG024824"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21-AG059206\/R33-AG059206"],"award-info":[{"award-number":["R21-AG059206\/R33-AG059206"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR00457"],"award-info":[{"award-number":["UL1-TR00457"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019346","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA046592"],"award-info":[{"award-number":["P30-CA046592"]}],"id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,1,28]]},"DOI":"10.1080\/10428194.2024.2419375","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:44:29Z","timestamp":1730105069000},"page":"190-203","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice"],"prefix":"10.1080","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-9750","authenticated-orcid":false,"given":"Matthew J.","family":"Pianko","sequence":"first","affiliation":[{"name":"Rogel Cancer Center, Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira S.","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Schoenbeck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of California, San Francisco, CA, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology, San Francisco VA Medical Center, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Nebraska Medical Center\/Nebraska Medicine, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2016.08.001"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0918-6"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.075051"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33658"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30220-5"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162693"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254235"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00779-2"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.18.00043"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00172-6"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.03.022"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-02993-w"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/62.7.722"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/56.3.m146"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afl041"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24532"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.12.004"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01488-8"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00626-4"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26172"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26319"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001965"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846500.86746.52"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846476.91419.a1"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8040"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03143"},{"key":"e_1_3_4_32_1","unstructured":"Smits F. Dynamic frailty status enables better prediction of survival probability \u2013 results of the HOVON 143 study. 65th ASH Annual Meeting & Exposition [Internet]; 2023 [cited 2024 May 5]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper180006.html."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188672"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0592"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-8-24"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158277"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01247-9"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02433-6"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00524-1"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0013"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.101"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afab211"},{"issue":"8","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/10428194.2024.2340052","article-title":"Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)","volume":"65","author":"Haider I","unstructured":"Haider I, Leong DP, Louzada M, et\u00a0al. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leuk Lymphoma. 65(8):1167\u20131174.","journal-title":"Leuk Lymphoma"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.08.004"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2022.04.010"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.08.002"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133469"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.015"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000792"},{"key":"e_1_3_4_52_1","unstructured":"US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services Food and Drug Administration [Internet]; 2022. Available from: https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00515"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33238"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00602-4"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.017"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02392-6"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116920"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279160"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-0953-4"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.267757"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2264-0"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0272-0"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3449-8"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_3_4_66_1","unstructured":"MMRF CoMMpass Study [Internet]. Multiple Myeloma Research Foundation; 2018 [cited 2022 Dec 17]. Available from: https:\/\/themmrf.org\/we-are-curing-multiple-myeloma\/mmrf-commpass-study\/.Google.Scholar."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125749"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16945"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136292"},{"key":"e_1_3_4_71_1","first-page":"27","article-title":"Ixazomib-based induction followed by single-agent ixazomib maintenance in transplant ineligible, newly diagnosed multiple myeloma patients: updated results of the EMN10-unito trial","volume":"5","author":"Mina R","year":"2021","unstructured":"Mina R, Larocca A, Corradini P. Ixazomib-based induction followed by single-agent ixazomib maintenance in transplant ineligible, newly diagnosed multiple myeloma patients: updated results of the EMN10-unito trial. HemaSphere. 2021;5:27\u201328.","journal-title":"HemaSphere"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146274"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146650"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.240374"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136293"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03101-z"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.226407"},{"key":"e_1_3_4_78_1","unstructured":"Frailty-stratified randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) \u2013 the FRAIL-M study [Internet]. Australian New Zealand Clinical Trials Registry (ANZCTR); 2019 [cited 2024 Sep 30]. Available from: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12619001199101."},{"key":"e_1_3_4_79_1","unstructured":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017-03) [Internet]. Clinicaltrials.gov; 2019 [cited 2024 Sep 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03993912."},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000936156.32733.12"},{"key":"e_1_3_4_81_1","first-page":"3146","article-title":"Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87\/Nmsg-18 study group","volume":"130","author":"Stege C","year":"2017","unstructured":"Stege C, Van Der Holt B, Mellqvist U-H. Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87\/Nmsg-18 study group. Blood. 2017;130:3146\u20133146.","journal-title":"Blood"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7507"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8000"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181444"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25726"},{"key":"e_1_3_4_86_1","unstructured":"Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone (LENDER). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03809780. Accessed 24 October 2024."},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0581-8"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189969"},{"key":"e_1_3_4_89_1","unstructured":"Nakazato T. A phase II clinical trial to verify the efficacy safety and infection prevention effect of combination therapy with clarithromycin lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed\/refractory multiple myeloma [Internet]. UMIN Clinical Trials Registry; 2020 [cited 2024 Oct 1]. Available from: https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&recptno=R000015621&type=summary&language=E."},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003695660"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2419375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:24:00Z","timestamp":1737462240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2419375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"alternative-id":["10.1080\/10428194.2024.2419375"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2419375","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}